Latest Trends and Innovations in Multiple Myeloma Management at EHA 2024

Now Viewing

EP: 1.Latest Trends and Innovations in Multiple Myeloma Management at EHA 2024

EP: 2.EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma

EP: 3.PERSEUS Trial Findings at EHA 2024

EP: 4.Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

EP: 5.EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

EP: 6.EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

EP: 7.Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch

Video content above is prompted by the following:

• What are the latest trends and innovations you have observed in the treatment and management of multiple myeloma leading up to the European Hematology Association Hybrid Congress?
• Let’s begin first with newly diagnosed multiple myeloma (NDMM). How has the paradigm of NDMM management shifted in recent history?